Drug
Nab-paclitaxel
CI-DRUG-00000397Explore in graph →NCIt C2688 CIViC
Regulatory
Approvals (0)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
Data not yet available
No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.
What CancerIndex knows
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Phase4 | Phase 4 | 282 | 146 | 111 | 749 | 0 | — | — | 2003-09 |
| Malignant Pancreatic Neoplasm | Phase4 | Phase 4 | 87 | 40 | 23 | 230 | 0 | — | — | Nov 1, 2006 |
| Malignant Breast Neoplasm | Phase4 | Phase 4 | 51 | 24 | 32 | 151 | 0 | — | — | Jun 1, 2004 |
| Malignant Lung Neoplasm | Phase4 | Phase 4 | 47 | 22 | 21 | 111 | 0 |
Curated evidence
Clinical evidence (2)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 41974716
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PIK3CA Mutation1 | ||||||||
| Nab-paclitaxel | HER2-Positive Breast Carcinoma | |||||||
Clinical trials
Trials with this intervention (754)
Most recently updated first, 50 per page.
clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02405910 | Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC. | withdrawn | Phase 2 | 0 | West Virginia UniversityOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT02076243 | Treatment With Nab-paclitaxel in Cutaneous SCC | terminated | Phase 2 | 2 | Icahn School of Medicine at Mount Sinai |